InMed Pharmaceuticals Inc - Asset Resilience Ratio
InMed Pharmaceuticals Inc (INM) has an Asset Resilience Ratio of 0.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check InMed Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how InMed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See net asset quality index of InMed Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down InMed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is InMed Pharmaceuticals Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $41.62 Million | 0.46% |
| Total Liquid Assets | $41.62 Million | 0.46% |
Asset Resilience Insights
- Limited Liquidity: InMed Pharmaceuticals Inc maintains only 0.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
InMed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare InMed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for InMed Pharmaceuticals Inc (2001–2025)
The table below shows the annual Asset Resilience Ratio data for InMed Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.21% | $43.56K | $21.23 Million | -0.15pp |
| 2022-06-30 | 0.35% | $57.69K | $16.46 Million | -0.12pp |
| 2021-06-30 | 0.48% | $57.46K | $12.10 Million | -0.07pp |
| 2020-06-30 | 0.54% | $42.38K | $7.80 Million | -25.56pp |
| 2019-06-30 | 26.10% | $3.93 Million | $15.07 Million | +17.75pp |
| 2018-06-30 | 8.35% | $1.78 Million | $21.34 Million | +5.59pp |
| 2003-06-30 | 2.75% | $32.04K | $1.16 Million | -45.03pp |
| 2002-06-30 | 47.78% | $651.24K | $1.36 Million | +1.80pp |
| 2001-06-30 | 45.98% | $2.15 Million | $4.67 Million | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more